Emergent BioSolutions (EBS) Return on Capital Employed Growth (5y) (2016 - 2026)
Emergent BioSolutions (EBS) Return on Capital Employed Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn |
| 3 | Zoetis | 32.69 Bn | 30.75 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 383.02 Mn | 221.52 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,614.00 |
| Dec 31, 2025 | -1,038.00 |
| Sep 30, 2025 | -221.00 |
| Jun 30, 2025 | -442.00 |
| Mar 31, 2025 | -1,381.00 |
| Dec 31, 2024 | -1,395.00 |
| Sep 30, 2024 | -1,361.00 |
| Jun 30, 2024 | -4,318.00 |
| Mar 31, 2024 | -4,925.00 |
| Dec 31, 2023 | -6,617.00 |
| Sep 30, 2023 | -6,628.00 |
| Jun 30, 2023 | -4,463.00 |
| Mar 31, 2023 | -2,778.00 |
| Dec 31, 2022 | -2,256.00 |
| Sep 30, 2022 | -650.00 |
| Jun 30, 2022 | -541.00 |
| Mar 31, 2022 | -134.00 |
| Dec 31, 2021 | 97.00 |
| Mar 31, 2021 | -1,392.00 |
| Dec 31, 2020 | -802.00 |